Friday, December 14, 2018

Professional Societies Disclose Their Disclosure Policies, But Why Won’t Some Discuss Them?

Last month I wrote about “How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall?” The article dealt with the fallout of Baselga’s failure to disclose millions of dollars he had received from industry, and his subsequent resignation as Memorial Sloan Kettering Cancer Center’s physician-in-chief as well as from a number of corporate boards. The disclosure issue had initially...

Fixing Our Flawed Drug Development Pipeline by Applying One Fundamental Tech Principle

I was diagnosed with invasive ductal carcinoma in May of 2014. Fortunately, my cancer was early stage, I didn’t require aggressive chemo, and I’m nearing my five-year remission milestone. Despite having worked at the National Institutes of Health (NIH) on clinical trials and in pharma for much of my career, I didn’t appreciate all sides of the drug development process...

Otis Brawley Discusses Life After Leaving the American Cancer Society

When Otis W. Brawley, MD — who had served as the face of the American Cancer Society (ACS) for the past 11 years—resigned earlier this month as the organization’s senior vice president and chief medical and scientific officer to pursue new opportunities at an as-yet-to-be disclosed major university, many members of the cancer community were surprised and shocked. Brawley had...

How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall?

In the aftermath of the fall of renowned breast cancer researcher Jose Baselga, MD, PhD, following revelations last month of his failure to disclose millions of dollars in payments from industry, I reached out to learn a little bit more about current institutional conflict of interest policies, especially in light of the current trend promoting academic-governmental-industry collaborations in research. Although...

Opioid Prescribing and Cancer Pain – Contemporary Challenges

Each year, about 1.7 million Americans are diagnosed with cancer, and about 600,000 die from cancer. Fortunately, there are now over 16 million cancer survivors in the U.S. We know that pain is an issue for cancer patients, especially with advancing disease bringing about the end of life. We also know that cancer survivors may be plagued by chronic...

John McCain Dies of Glioblastoma at Age 81

Senator and former presidential candidate John Sidney McCain III died today, August 25, 2018. He was 81 years old. McCain died at his home in Cornville, Arizona after more than a year-long fight with glioblastoma (GBM), a complex and aggressive form of brain cancer. There are few effective treatment options for patients. According to the American Brain Tumor Association, the...

Stronger by Sharing: 5 Reasons Why It’s Important to Share Your Story

Bursts of laughter, tears of joy, sobs of sadness, love, grief, anger, it is all part of our story we call ‘Life’. It is a journey, a quest to pursue happiness. There are ups and downs, highs and lows, for some more extreme than others, but either way there are so many stories out there. Stories that are worth telling! With...

Why Do We Need a Right-to-Try Bill in America?

Congress recently passed, and President Trump signed, the “Right to Try” bill that gives dying patients limited access to drugs that have not yet been approved by the U.S. Food and Drug Administration (FDA). Our Founders would be astonished that we need such a bill. Nowhere does the U.S. Constitution give the federal government the authority to regulate the practice...

New York Times Editorial Advocates for Policies that Could Hurt Patients

In an editorial published on Friday, June 8, 2018, in The New York Times (Easier Drug Approval Isn’t Cutting Drug Prices), the Times Editorial Board claims that the U.S. Food and Drug Administration (FDA) is lowering standards by working to get treatments to patients more quickly and instituting a less regulation approach to reviewing new drugs and medical devices. The...

A Key-Hole View on Healthcare Disparity

The topic of healthcare disparity has been discussed in many forums and many articles have been written to bring about awareness, debate the issue, find fault in the system, and make assumptions on what the right solution is.  I am, by no means, an expert on this topic but I believe that healthcare economic burdens are paramount everywhere. Patients experience substantial...

Related articles